A Rare Case Report of Immunoglobulin D Subtype Multiple Myeloma Complicated With Hyperlipidemia

Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous cytogenetic abnormalities. In most cases, patients suffering from multiple myeloma typically display normal or decreased blood lipid concentrations. We herein present a case of immunoglobulin (Ig) D‐λ subtype multiple myeloma with concurrent hyperlipidemia. This patient presented with elevated lipid levels upon lenalidomide, bortezomib, and dexamethasone (RVD) chemotherapy with triglycerides of 4.12 mmol/L (reference range: 0.4–1.7 mmol/L), total cholesterol of 6.71 mmol/L (reference range: 3.12–5.72 mmol/L), low‐density lipoprotein cholesterol of 4.29 mmol/L (reference range: 1.04–1.96 mmol/L), and lipoprotein(a) of 582 mg/L (reference range: 0–300 mg/L), which showed typical symptoms of hyperlipidemia. After chemotherapy cycles, the elevated lipid indicators were gradually decreased (or close) to normal levels without any antihyperlipidemia drug or therapy. This report analyzed a rare hyperlipidemic multiple myeloma case and may provide insights into the safety and guidance of the procedure for clinical diagnosis and treatment.